Zhao, Dan

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., et al. (2023) · New England Journal of Medicine

Glioma Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 814

Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion

Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell

Cancer, Hypoxia, and MetabolismBiochemical and Molecular Research

Cited by 433

Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH -Mutant Gliomas

Wakimoto, H., Tanaka, S., Curry, W. T., Loebel, F., Zhao, D., Tateishi, K., Chen, J., Klofas, L. K., Lelic, N., Kim, J. C., et al. (2014) · Clinical Cancer Research

Glioma Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 190

Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma

Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., et al. (2024) · npj Precision Oncology

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 93

Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Zhao, D., Li, H., Mambetsariev, I., Mirzapoiazova, T., Chen, C., Fricke, J., Kulkarni, P., Villaflor, V., Arvanitis, L., Hamilton, S., et al. (2022) · Cancers

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 24